Corneregel

Quick links to important sections

Corneregel

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Corneregel

What is Corneregel?

Corneregel is a topical ophthalmic formulation designed to support the healing and protection of the ocular surface. It is primarily characterized by its high viscosity and its active component, which aids in the maintenance of the corneal and conjunctival tissues.

Composition and Mechanism

The primary active ingredient in Corneregel is dexpanthenol, a derivative of pantothenic acid (vitamin B5). When applied to the eye, dexpanthenol acts as a precursor that contributes to the regeneration of mucous membranes and the corneal epithelium.

In addition to the active substance, the formulation contains a carbomer base. This synthetic polymer creates a high-viscosity gel that forms a stable, protective film over the surface of the eye. This film serves several purposes:

  • Extended Contact Time: The gel structure allows the active ingredient to remain on the ocular surface longer than standard liquid eye drops.
  • Hydration: It helps retain moisture on the cornea, preventing the surface from drying out.
  • Physical Protection: It acts as a mechanical lubricant, reducing friction between the eyelid and the cornea during blinking.

Clinical Application

Corneregel is utilized in clinical settings to manage conditions involving damage to the outermost layers of the eye. Its properties make it suitable for assisting the natural recovery process of the ocular tissue. By providing a moist environment and the necessary components for cellular repair, it supports the integrity of the corneal structure.

What side effects are possible with Corneregel?

Possible side effects and safety information

The official safety profile for Corneregel (Dexpanthenol ophthalmic gel) is structured around potential ocular effects and formal regulatory restrictions, as documented in government sources.


Documented Adverse Reactions and Frequency

Adverse reactions are formally classified by frequency in regulatory documents, covering effects on the eye and the immune system.

Frequency Classification Documented Adverse Reactions
Very Rare (may affect up to 1 in 10,000 people) Hypersensitivity reactions (e.g., itching, rash)
Not Known (frequency cannot be estimated) Eye irritations (e.g., redness, pain, foreign body sensation, increased tearing, conjunctival swelling)

These effects are formally categorized under Eye Disorders and Immune System Disorders in regulatory system-organ class groupings.


Safety Considerations and Restrictions

Duration-Related Safety Pattern: A key safety note in the official labeling relates to the preservative, Cetrimide. Long-term and frequent application of the gel is associated with the potential for corneal epithelium damage due to this preservative.

Restrictions: The medicine is formally contraindicated in individuals with a known hypersensitivity to Dexpanthenol or any of the other ingredients in the formulation.

Ocular Effects: Due to the viscous gel formulation, the application may temporarily cause blurred vision immediately after use.

Population Note: A regulatory caution exists for use during Pregnancy and Lactation, due to the uncertainty about the extent of systemic absorption of the active ingredient.

Overdose and Emergency Response

Overdose of Corneregel

Corneregel contains the active substance Dexpanthenol (also known as pantothenic acid or vitamin B5), which is widely considered safe for topical use in the eye. Based on the pharmacological properties of Dexpanthenol and its use as an eye preparation, the risk of serious complications from an overdose is generally considered low.

Specifically for ophthalmic use, accidental excessive application of Corneregel is not associated with known systemic or local toxic risks. The therapeutic effect is not enhanced by using a greater amount than recommended. In cases of accidental overapplication, the primary concern would be localized, temporary irritation due to the formulation's components, which may include mild stinging, redness, or a foreign body sensation.

When to Seek Help

While an overdose of Corneregel is not expected to cause severe toxicity, medical attention should be sought in the following circumstances:

  • Accidental Oral Ingestion: If a large amount of the eye gel is swallowed, contact a poison control center or seek medical assistance. While the active ingredient has low toxicity, supportive and symptomatic care may be necessary.
  • Persistent or Worsening Symptoms: Stop using the product and consult an eye care professional or physician if you experience an increase in side effects such as eye irritation, pain, persistent redness, or a decline in visual acuity. These symptoms may indicate an underlying condition or an allergic reaction, which, although rare, requires professional assessment.
  • Signs of Allergic Reaction: Seek immediate emergency medical care if you develop signs of a severe allergic reaction, which may include difficulty breathing, significant swelling of the face, lips, tongue, or throat, or a widespread rash.

Therapeutic Uses of Corneregel

What Corneregel Treats: Main Uses and Benefits

The primary therapeutic role of Corneregel is to provide supportive symptomatic relief for conditions affecting the eye's front surface. It is designed to ease the overall symptom burden, particularly during periods when ocular discomfort or irritation is noticeable and interferes with daily comfort. The application of Corneregel is used across domains where additional symptomatic support is needed.


Easing Acute Discomfort in Corneal Surface Conditions

This medication is used in situations involving acute, distressing symptomatic discomfort associated with the cornea and conjunctiva. It is applied across domains where additional symptomatic support is needed to help manage symptom clusters like burning or foreign body sensation.

Commonly, Corneregel is used across conditions characterized by episodic or fluctuating symptom patterns arising from physical damage, such as corneal erosions, lesions, or burns, and in adjuvant care for specific ocular presentations. The key benefit is to offer symptomatic relief that helps patients cope more steadily with difficult episodes and supports improved day-to-day comfort.

“It provides support that helps ease the overall symptom burden during periods of heightened symptoms.”


Quick Fact: Relief for Noticeable Functional Strain


Supportive Management in Symptom-Driven Scenarios

The medication is relevant in clinical settings requiring temporary assistance in symptom stabilization, often used during phases when symptoms become more noticeable as part of the overall management plan. It is used in areas where short-term symptom management is appropriate, applied in scenarios where additional management of discomfort is required during acute or disruptive episodes. This supportive assistance helps maintain a sense of stability when symptoms become temporarily overwhelming.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Corneregel — Official Regulatory Information

This section outlines who is permitted to use Corneregel (Dexpanthenol Ophthalmic Gel) and who is restricted, based strictly on official governmental regulatory documents.


Populations for whom use is contraindicated

The medicine is contraindicated for individuals with a known hypersensitivity (allergy) to the active substance, Dexpanthenol, or to any of the inactive ingredients in the gel formulation.


Eligibility-Related Restrictions and Conditional Use

Category Regulatory Status (Official Wording)
Contact Lens Use Must not be used while wearing lenses. Lenses must be removed before application.
Pregnancy and Lactation Restricted/Conditional Use. The physician must “carefully weigh the benefits... against possible risks” due to unknown systemic absorption.
Age-Group Eligibility Generally suitable for adults. No universal, absolute contraindication is documented for older adults or children.
Systemic Comorbidities No known restrictions are documented in the official labeling based on conditions such as hepatic or renal impairment.

Connection to the overall eligibility profile: Regulatory documents establish an absolute prohibition based on component allergy and define conditional restrictions for pregnant or breastfeeding individuals due to the requirement for medical risk assessment. All other population groups are generally permitted to use the medicine under standard labeled conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents confirm that Corneregel (Dexpanthenol ophthalmic gel) has a focused interaction profile primarily related to its viscous formulation and topical administration route. No clinically relevant systemic interactions are expected or documented in regulatory labeling due to the medicine's negligible systemic exposure.

Interaction Scope

Category Official Regulatory Findings
Interacting product categories Other topical ophthalmic preparations (eye drops and eye ointments).
Mechanistic basis Local physical interference. The gel's high viscosity may interfere with the proper contact time or absorption of preparations co-administered at the same time.
Systemic interactions None documented for drug–drug, drug–food, drug–alcohol, or metabolic pathways.

Timing and Administration Constraints

Official labeling mandates a specific timing separation when Corneregel is co-administered with other topical eye medications. This is classified as an administration-timing constraint to prevent the physical interference of the gel.

  • Timing Rule: An interval of at least 15 minutes must be maintained between the application of Corneregel and any other eye drops or eye ointments.
  • Sequence Restriction: Corneregel must always be applied last among all co-administered ophthalmic preparations to ensure the preceding medications are properly absorbed onto the ocular surface.

This interaction structure reflects the drug's topical use, where constraints are localized to the eye's surface, with no formal contraindicated combinations or systemic pharmacokinetic alterations listed in official regulatory documentation.

Mechanism of Action

Pharmacodynamic Mechanism of Dexpanthenol

The action of Corneregel is mediated by Dexpanthenol, which functions as a metabolic precursor within corneal and conjunctival epithelial cells. Dexpanthenol is rapidly converted enzymatically into Pantothenic Acid, a molecular component mandatory for the synthesis of Coenzyme A (CoA). This metabolic enhancement increases the cellular CoA pool, which drives biosynthesis pathways critical for generating lipids and phospholipids necessary for cell membrane formation and stabilization.

The increased availability of CoA facilitates the physiological process of accelerated epithelial cell proliferation and migration. This cascade supports re-epithelization of the ocular surface and influences the re-establishment of the epithelial barrier function through trophic processes and contributions to tissue stabilization. Furthermore, the mechanism includes local anti-inflammatory modulation by reducing the activity of certain pro-inflammatory mediators, promoting a cellular microenvironment conducive to tissue restructuring.

Dosage and Administration Information

The administration of Corneregel is based on a structured protocol for topical ophthalmic application, which involves instilling the viscous gel directly into the conjunctival sac of the affected eye. The medication is presented as an ophthalmic gel containing 50 mg of Dexpanthenol per 1 g of formulation.

The standard dosing regimen specifies the application of one drop (or the equivalent of a strip approximately 1 cm long) into the affected eye. This is scheduled for administration up to four times daily, with an additional application consistently recommended before retiring for the night, resulting in a typical daily frequency of up to five administrations. Use is defined by a non-limited duration pattern, generally continuing until the condition or subjective symptoms have fully resolved.

Several procedural conditions govern proper use. If the gel is used in combination with any other eye drops or eye ointments, Corneregel must be administered last. A minimum interval of 15 minutes must separate the application of the gel from any prior ophthalmic product. Contact lenses must also be removed prior to instillation and should not be reinserted for at least 15 minutes afterward. Furthermore, for a missed application, it should be made up as soon as possible, but a double dose must not be used to compensate. This structured approach ensures standardized administration.

Recent Clinical Evidence

Corneregel: Research Evidence Overview

Research for Corneregel (Dexpanthenol ophthalmic gel) has examined its role, consistent with its classification as a substance classified as an epithelial regeneration stimulant and keratoprotective agent. Studies have explored its use in conditions involving the front surface of the eye, particularly the cornea and conjunctiva. This overview summarizes the structure of the existing research, the types of patient experiences monitored, and the areas where evidence remains limited.


Evidence for Epithelial Healing and Surface Support

Clinical evaluation primarily relies on short-term Randomized Controlled Trials (RCTs) examining Dexpanthenol use following physical damage, such as traumatic abrasions or surgical procedures. These studies monitored adult populations and focused on objective outcomes, specifically the time to complete re-epithelialization and the size of the epithelial defect. Research also was evaluated in contexts involving fluctuating or unstable symptoms often associated with Dry Eye Disease (DED), monitoring outcomes like tear film stability (TBUT) and patient-reported discomfort. Findings describe patterns observed in these studies compared to control agents, but reported outcomes were generally short-term.


Limitations and Areas of Research Uncertainty

Research into corneal structural outcomes utilized advanced imaging techniques, such as Confocal Microscopy, in specialized patient cohorts. This is an area where reported evidence is limited, and long-term effects are not fully established regarding sustained recovery or structural benefits. Data for certain groups remain insufficient, particularly for children or patients with systemic conditions affecting healing. A key limitation across the research is that Dexpanthenol was observed in studies as part of a combination formulation, which makes it challenging to definitively attribute all observed patterns to the Dexpanthenol ingredient alone. Comparative evidence is lacking against a broad range of alternative standard-of-care treatments, and long-term effects are not fully established for chronic conditions like Dry Eye Disease.

Frequently Asked Questions (FAQ)

Common questions about Corneregel (FAQ)

Q: What is the main reason Corneregel is prescribed by eye doctors?

Official regulatory indications state that Corneregel is used to support the healing process of damage to the cornea and conjunctiva, the transparent front layer and the lining of the eye. This includes supportive treatment for conditions such as corneal dystrophies, recurrent corneal erosions, and lesions that may result from burns or prolonged contact lens wear.


Q: Is Corneregel the same as other eye drops that use a similar ingredient?

The official documentation describes Corneregel as a viscous ophthalmic gel containing Dexpanthenol and specific inactive components. This unique formulation, which is thick and gel-like, is what distinguishes it from other products that might contain Dexpanthenol but are presented as simple liquid solutions.


Q: Does Corneregel help with dry eye syndrome?

Some official documentation indicates that the active ingredient, Dexpanthenol, can be used in formulations to support the healing of the eye's surface in specific conditions associated with dry eye, known medically as keratoconjunctivitis sicca. The medicine’s role is defined as supporting epithelial regeneration and the tissue.


Q: Can Corneregel be used with contact lenses?

Official instructions specify that contact lenses must be removed before the gel is applied to the eye. The lenses should not be reinserted for approximately 15 minutes afterward. This precaution is advised because the ingredients, such as the preservative, may interact with and potentially discolor the lens material.


Q: What is the difference between Corneregel and simple artificial tears?

Corneregel is classified in official documents as an epithelial regeneration support agent, meaning its primary function is to support the healing and recovery of the cornea and conjunctiva. Simple artificial tears, conversely, are typically classified as lubricating agents. The difference is related to Corneregel's classification as an epithelial regeneration support agent, in contrast to simple lubricating agents.


Q: Is it normal to have blurry vision right after putting in Corneregel?

Official product information states that Corneregel may temporarily cause blurred vision or streaks immediately after application. This effect is described in product information due to the medicine’s viscous (thick) gel formulation, which is designed to ensure prolonged contact with the eye's surface.


Q: Does Corneregel contain preservatives?

Yes, regulatory formulation documents confirm that the medicine contains the preservative Cetrimide. Official warnings note that long-term and frequent use of products containing this preservative may be associated with potential damage to the surface of the eye (corneal epithelium).


Q: What if I forget to use Corneregel at the planned time?

Official instructions advise that if an application is missed, it should be made up as soon as possible. However, official instructions specify that a double dose must not be used to compensate for a single missed application.


Q: Can children use Corneregel?

Regulatory documents do not list a universal, absolute prohibition (contraindication) for the use of Corneregel in children. However, the available research evidence is described as limited for this age group, and the decision to use in any population requires assessment.


Q: Does alcohol consumption affect the use of Corneregel?

Official regulatory documents do not state any known, clinically relevant systemic interactions between this topical ophthalmic gel and alcohol consumption. This is consistent with the medicine having negligible systemic absorption.


Q: Do people ever use Corneregel for general eye discomfort?

The official purpose of the medicine is specifically defined as supporting the healing and regeneration of the eye's surface following damage. Its official use is described as supporting tissue repair, rather than being indicated for general, unspecified eye discomfort.


Q: Is there a generic version of Corneregel?

The active substance in Corneregel, Dexpanthenol, is an established ingredient that appears in multiple ophthalmic formulations internationally. Some regulatory databases list Corneregel itself as being available as a generic medication in certain regions.


Q: What if I accidentally put too much Corneregel in my eye?

Official documentation specifically addresses this concern, stating that the administration of a larger amount of the medicine than recommended is not associated with any additional risk. The medicine is primarily localized to the surface of the eye.


Q: Can pets use Corneregel (for example, if a veterinarian prescribes it)?

Corneregel is officially regulated and labeled as a medicine for human use. While the active substance Dexpanthenol may be used in veterinary medicine under specific governmental guidelines, the product itself is prepared and approved for human patients.


Q: Is Corneregel used after eye surgery?

Official indications for the medicine include supporting the healing process of damage to the cornea and conjunctiva. This supportive role can be consistent with the healing required following certain surgical procedures that affect the eye's surface tissues.


Q: Is a stinging or burning sensation common when first starting Corneregel?

Official documents list eye irritations, which can include burning and a foreign body sensation, as potential adverse reactions. The frequency of these reactions cannot be estimated based on the available safety data.


Q: What kind of eye injuries is Corneregel typically used for?

Official therapeutic indications state that Corneregel is used for damage to the surface of the eye, which may include injuries such as recurrent corneal erosions, trauma from contact lens wear, and lesions resulting from chemical or other types of burns.


Q: Why is Corneregel usually applied at night?

Official instructions consistently recommend one administration be applied just before retiring for the night. This timing is a practical choice for viscous eye gels, as the temporary blurring of vision that may occur after application is less disruptive during sleep.


Q: Does Corneregel interact with herbal supplements?

Official regulatory documents do not list any specific warnings against using Corneregel with herbal supplements. This lack of documented interaction is consistent with the medicine's negligible systemic absorption.


Q: Can I share my Corneregel with another person?

To prevent contamination, the product is intended for use by a single patient. Regulatory guidance focuses on preventing contamination by avoiding contact between the tube tip and any surface.


Q: How long after opening the tube can Corneregel be used?

The official in-use shelf-life is listed as a maximum of 6 months after the tube has been opened for the first time. This limit helps ensure the quality and integrity of the gel after the seal has been broken.


Q: Is Corneregel available in single-dose units?

Regulatory and manufacturer product information indicates that Dexpanthenol ophthalmic gel is produced in multiple formats. This includes both the standard multi-dose tubes and preservative-free single-dose units in certain markets.


Q: What should I do if my tube of Corneregel looks discolored?

Official guidance warns against using the product if its appearance has changed, which includes if the gel appears discolored. A change in color may indicate contamination or product degradation, and official guidance warns against using the medicine in this state.


Q: Are there any official warnings about using Corneregel with other eye medications?

The official warning is an administration-timing constraint. Corneregel is a viscous gel and must always be applied last among all co-administered ophthalmic preparations, with a minimum interval of 15 minutes required between applications.


Q: Is Corneregel used to treat corneal ulcers?

While the medicine’s role is primarily supportive, its official indications include supportive treatment for the healing process in cases of bacterial, fungal, and viral damage to the cornea, which can be associated with ulcers.

--ุทn### Q: What is the typical duration of treatment with Corneregel?

Official labeling defines the use by a non-limited duration pattern, generally continuing until the condition or subjective symptoms have fully resolved. The medicine may also be suitable for long-term use, provided cautions related to the preservative are followed.


Q: Do regulatory agencies classify Corneregel as a high-risk medication?

Regulatory documents list a limited number of adverse reactions, which are primarily localized to the eye, and the medicine is not associated with systemic side effects. The main regulatory caution relates to the potential for damage to the corneal epithelium from the preservative Cetrimide with long-term, frequent use.


Q: What are the ingredients in Corneregel besides the main active component?

In addition to the active component, Dexpanthenol, the official list of other ingredients (excipients) in the formulation includes Cetrimide (a preservative), Carbomer (a thickening agent), sodium edetate, sodium hydroxide, and water for injections.


Q: Why do some people experience mild eye redness after using Corneregel?

Eye redness is listed as an official adverse reaction in product information. Additionally, official warnings note that the preservative Cetrimide, especially with long-term and frequent application, can cause general irritation of the eyes, which can include redness.

How should Corneregel be stored and disposed of?

How to Store and Dispose of Corneregel

Corneregel must be stored according to official regulatory specifications to maintain product quality and safety.


Storage Requirements

The medicine must not be stored above 25 C. The tube must not be stored without its cap put on to maintain its integrity. For safety, this medicine must always be kept out of the sight and reach of children.

Stability Requirement Condition
In-Use Shelf-Life Do not use for longer than 6 months after opening the tube.
Expiration Do not use after the expiry date printed on the packaging.

Disposal

To comply with environmental regulations, do not throw away unused or expired Corneregel via wastewater or household waste.

Disposal must be managed by professional waste handling; you must ask your pharmacist how to dispose of any medicine you no longer need.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Corneregel found in:

A-Z Index: